Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Introduction: Up to the present, have been few studies with pentamidine in the Americas; and
there is no consensus regarding the dose used.
Objectives: To evaluate the use of pentamidine in single dose, double and triplo in the
treatment of cutaneous leishmaniasis.
Methods: Clinical trial of phase II pilot study with 159 patients. Pentamidine will be used
at a dose of 7 mg/kg, in three arms: single dose, double dose and triple dose. They will be
also assessed the safety and adverse effects. The sic will be reviewed one, two and six
months after the end of the treatments.
Phase:
Phase 2
Details
Lead Sponsor:
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado